Actively Recruiting

Phase Not Applicable
Age: 14Years +
FEMALE
Healthy Volunteers
ID06951438

STI Self-swab Testing At the Time of Telemed Medication Abortion Provision

Led by Queen's Medical Center · Updated on 2025-06-26

75

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

Sponsors

Q

Queen's Medical Center

Lead Sponsor

U

University of Hawaii Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of at-home, self-collected STI testing during telemedicine medication abortion care. The study aims to understand how acceptable, feasible, and utilized this self-swab testing is compared to traditional in-clinic STI testing among patients seeking medication abortion. It also seeks to compare STI positivity rates between telemedicine and in-clinic patients and assess the time between testing and treatment for positive cases. The study involves patients receiving telemedicine medication abortion care who will be offered a self-collection kit for testing gonorrhea, chlamydia, and trichomonas. Participants will collect specimens before starting their medication abortion and send them to a lab using prepaid postage. They will complete a survey on demographics, acceptability, and feasibility after specimen submission. The self-swab kit is included in the mailed abortion medication package, and results are securely communicated to patients and their medical records. A control group includes patients receiving in-clinic medication abortion, with data collected retrospectively. Participants will engage in telemedicine visits for consent and instruction, self-collect and mail specimens, and complete follow-up surveys. Testing is processed at a central lab, with support provided if specimens are inadequate. Positive results prompt timely treatment referrals. The study monitors utilization, acceptability, feasibility, STI positivity rates, and treatment timelines. The study is expected to last up to one year, with surveys completed within two weeks after specimen collection.

CONDITIONS

Brief Title

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

Who Can Participate

Age: 14Years +
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients seeking telemedicine medication abortion at Queen Medical Center Options Center clinic
  • Patients who need or desire STI testing according to CDC guidelines
  • Female patients aged 14 and older
  • Able to speak and read English
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Home address outside the state of Hawai'i
  • Currently incarcerated
  • Unwilling to perform vaginal swab collection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit (telemedicine)

Self-swab Collection

Duration - Up to 2 weeks

Participants who enroll will receive a self-swab collection kit included with their medication abortion kit. They will collect their specimens at home before starting the medication abortion and send the samples to the lab using prepaid mailers.

No in-person visits; specimen collection and mailing done at home

Follow-up Survey and Results Notification

Duration - Up to 2 weeks after specimen receipt

After the lab receives the specimen, participants will complete a survey assessing acceptability and feasibility of the self-swab. Participants will receive their test results via phone, text, or email and be offered treatment if positive.

1 follow-up telemedicine contact (survey and results notification)

Medication Abortion Follow-up

Duration - 1 to 2 weeks after initial consultation

Participants typically attend a follow-up visit 1 to 2 weeks after the initial consultation to discuss medication abortion progress and may be reminded about specimen submission if not already sent.

1 scheduled follow-up visit (in-person or telemedicine)

Trial Site Locations

Total: 1 location

1

Queens Medical Center, 1004 Clinic POB1

Honolulu, Hawaii, United States, 96813

Actively Recruiting

Loading map...

Research Team

O

Olivia H Manayan, MD, MPH

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Similar Trials

Doxi-Rio: Pilot Implementation of Post-exposure Prophylaxis ...

Sexually Transmitted Diseases

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Fully integrated e-services for prevention, diagnosis, and treatment of sexually transmitted infections: results of a 4-county study in California.

Freya Spielberg, Vivian Levy, Shelly Lensing...

https://pubmed.ncbi.nlm.nih.gov/25320878

Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis.

Carole Lunny, Darlene Taylor, Linda Hoang...

https://pubmed.ncbi.nlm.nih.gov/26168051

Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.

Courtney Kerestes, Sarah Murayama, Jasmine Tyson...

https://pubmed.ncbi.nlm.nih.gov/33789080